Experiences with

Myeloproliferative neoplasm (MPN)

https://powerfulpatients.org/2024/09/18/myeloproliferative-neoplasm-care-gaps-effective-strategies-to-improve-care/ There is a lot of good information packed into a very short presentation. Key takeaways 1. Shared decision making is critical. 2.

"The JAK2 V617F mutation is the most common driver gene in myeloproliferative neoplasm (MPN), which means that the JAK/STAT signaling pathway is persistently activated independent of cytokines, and plays an important part in the onset and development of MPN.

[i]'in order to have a diagnosis of myeloproliferative neoplasm one needs a mutation and currently we do not have one' [/i](my follow up letter from clinic) Which I sort of understand / have always understood I do not have Primary PV.

[/i] [i] [/i] [i]https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2823017[/i] [i] [/i] [i]Within the HMN cohort, the most common diagnoses were myeloproliferative neoplasm (127 patients [19.0%]), chronic leukemia (106 patients [15.9%]), and multiple myeloma (97 patients [14.5%]).

Hi All, toddyboo here, I was just wondering if there were any PBCers out there who have PBC along with an MPN? The reason I ask is I have essential thrombocythemia and have just been diagnosed with PBC and wanted to see if there were any PBCers who also might have a similar diagnoses.

My bloodwork shows an elevated alk phos level (over time), positive AMA, GGT, DSDNA and I also was recently diagnosed last year with an MPN (myeloproliferative neoplasm) called essential thrombocythemia (which is a form of blood cancer as well as a gene mutation called JAK2 v617f).

Yesterday was the first time I went back to see the original NHS haematologist who is now saying he believes its not a myeloproliferative neoplasm (MPN), but a genetic disorder (G6PD), however, the private haematologist already knew I had the disorder and ruled that out as a reason for my high platelets

MF is a rare but chronic myeloproliferative neoplasm characterized by bone marrow fibrosis. INCA033989 is a newly discovered high-affinity, fully human monoclonal antibody that selectively targets mutant calreticulin-mediated oncogenesis.

[/i] Nearly 80% of patients living with a myeloproliferative neoplasm (MPN) are affected by fatigue. Can digital health alleviate symptom burden in MPN care? What exactly is mobile app intervention, and how can it help me?

Nearly 80% of patients living with a myeloproliferative neoplasm (MPN) are affected by fatigue. Can digital health alleviate symptom burden in MPN care? What exactly is mobile app intervention, and how can it help me? Register to join this webinar moderated by a patient to learn about: 1.

Is the use of technology accelerating progress in myeloproliferative neoplasm (MPN) care? Why should MPN patients keep telemedicine in their toolbox post-COVID?

PV is the most common myeloproliferative neoplasm (MPN) and a long-term, potentially life-threatening disease with limited treatment options.

PEN (Patient Empowerment Network) is hosting a MPN webinar on Tuesday, 9 August 2022, entitled “Can I Get the Best Myeloproliferative Neoplasm (MPN) Care?”

Upcoming presentation by Dr. Claire Harrison w/ guest Dr. Nicole rochester. [i]With so many exciting developments in the research pipeline for myeloproliferative neoplasms (MPNs), how can I access the best possible MPN care? Will there be alternate treatment strategies for MPN patients who have failed

Thanks “Pegylated interferon alpha – 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial”, Leukeamia Research 54 (2017) 73-77, coauthored by Rueben Mesa: For the cohort of 75 patients there was “transaminitis at grade 1 in 6 patients (8%) and grade

In about 20% of people with myelofibrosis, if left unchecked, this severe type of myeloproliferative neoplasm (MPN) can transform to acute leukaemia. “We still don’t know why some patients progress quickly and some slowly.

« …Furthermore, a novel observation was that no individuals with a myeloproliferative neoplasm were found in cases with an allele burden below 2%, which may represent a cut-off point of disease versus no disease for JAK2V617F mutation positive individuals ». https://www.ncbi.nlm.nih.gov/pmc/articles/

https://www.cancertherapyadvisor.com/home/news/conference-coverage/american-society-of-hematology-ash/ash-2021/myeloproliferative-neoplasm-excess-mortality-younger-patient/

My name is Anna, I was officially diagnosed by BMB of a Myeloproliferative Neoplasm, Essential Thrombocytosis in December 2011. I have been aware of the condition due to the consistently high platelets counts since I got a DVT while travelling in 1999.

(I just noticed Manouche posted on this last year, anyway maybe some new details here) "JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML" and "A knockout combination for MPN stem cells" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7579737/ https://www.ncbi.nlm.nih.gov